{"entity":{"id":"nct06206174","kind":"trial","name":"TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies","aka":[],"tldr":"A phase 1/2 trial of TGRX-814 in non-Hodgkin lymphoma, acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplastic syndromes / neoplasms, run by Shenzhen TargetRx Co., Ltd., now recruiting.","summary":"TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies is a phase 1/2 interventional study registered as NCT06206174 by Shenzhen TargetRx Co., Ltd., with 30 participants planned, started 2024-03-06 and due to reach its primary completion in 2025-02-28. Interventions recorded: TGRX-814.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06206174","url":"https://clinicaltrials.gov/study/NCT06206174"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","aml","all-leukemia","mds"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["shenzhen-targetrx"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06206174","phase":"1/2","setting":"A Single-arm, Open-label, Dose Escalation and Expansion Phase I/II Study Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-814 Monotherapy and Combination Therapy in Patients With Hematological Malignancies","sponsor":"Shenzhen TargetRx Co., Ltd.","enrolled":30,"outcomes":[]},"route":"/trials/nct06206174/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"company":[{"id":"shenzhen-targetrx","kind":"company","name":"Shenzhen TargetRx","route":"/companies/shenzhen-targetrx/"}]}}